Skip to main content
RUBICON RESEARCH LIMITED logo

RUBICON RESEARCH LIMITED — Investor Relations & Filings

Ticker · RUBICON ISIN · INE506V01022 LEI · 335800GME6PCQIKP8T34 BSE.NS Manufacturing
Open in API
Filings indexed 116 across all filing types
Latest filing 2026-04-22 Legal Proceedings Report
Country IN India
Listing BSE.NS RUBICON

About RUBICON RESEARCH LIMITED

https://www.rubicon.co.in/

Rubicon Research Limited is a specialty organization focused on formulation development and the commercialization of value-added products. The company leverages proprietary drug delivery technology platforms to develop complex oral solids, liquids, topicals, and sterile dosage forms. Its core business activities encompass contract research and manufacturing services alongside the development of a diverse portfolio of Abbreviated New Drug Applications. The firm operates advanced research and development centers and manufacturing facilities that comply with stringent international regulatory standards. Rubicon Research emphasizes innovation in life cycle management and the enhancement of existing molecules to improve patient compliance and therapeutic outcomes. Its operations provide end-to-end solutions from initial concept and formulation design to commercial-scale production, serving global markets with a focus on high-quality, technology-driven solutions.

Recent filings

Filing Released Lang Actions
Intimation under regulation 30 read with Schedule III of the SEBI (Listing Obligation and Disclosure requirements) Regulations 2015 (Listing Regulations)
Legal Proceedings Report Classification · 95% confidence The document is an official communication addressed to stock exchanges (BSE and NSE) regarding the receipt of an Assessment Order from the Income Tax Authority for the Assessment Year 2023-24. It provides details about the order, including financial implications, penalties, and the company's response (filing an appeal). The document references SEBI Listing Regulations and SEBI Circulars, indicating it is a regulatory disclosure. The content is a notification of a regulatory/legal matter (tax assessment and related proceedings) rather than a full audit report or annual report. It does not contain financial statements or detailed audit results but rather informs about a legal/regulatory event affecting the company. Therefore, it fits best under Legal Proceedings Report (LTR). The document length is about 4862 characters, which is sufficient for a detailed announcement but not a full financial report. Hence, the classification is LTR with high confidence.
2026-04-22 English
Press Release
M&A Activity Classification · 95% confidence The document is a press release announcing the acquisition of Arinna Lifesciences Limited by Rubicon Research Limited. It includes details about the transaction, strategic rationale, financial terms, and expected closing timeline. The document is not a full financial report, audit, or regulatory filing but rather an announcement of a corporate transaction (M&A activity). It does not contain detailed financial statements or management discussion but focuses on the acquisition event. Therefore, the appropriate classification is M&A Activity (TAR). The document length (6405 characters) supports it being a detailed announcement rather than a brief notice or a full report.
2026-04-15 English
Press Release
M&A Activity Classification · 95% confidence The document is a press release announcing the acquisition of Arinna Lifesciences Limited by Rubicon Research Limited. It includes details about the transaction, strategic rationale, financial terms, and expected closing timeline. The document is not a full financial report, audit, or regulatory filing but rather an announcement of a corporate transaction (an acquisition). It does not contain detailed financial statements or management discussion but focuses on the acquisition event. Therefore, it fits best under the category of M&A Activity (TAR), which covers announcements and documents related to merger proposals or takeover bids.
2026-04-15 English
Acquisition
Capital/Financing Update Classification · 95% confidence The document is an official notification addressed to stock exchanges (BSE and NSE) regarding the acquisition of an 85% stake in Arinna Lifesciences Limited by Rubicon Research Limited. It references compliance with Regulation 30 of the SEBI Listing Regulations, which pertains to disclosure of material events. The content includes detailed information about the acquisition such as the target entity, industry, consideration, and background, but it is not a financial report or earnings release. It is an announcement of a corporate transaction (acquisition) rather than a merger filing or tender offer document. Therefore, the document fits best under the category of Capital/Financing Update (CAP), which covers updates on company fundraising, financing activities, or capital structure changes including acquisitions that result in subsidiaries. The document length is 7051 characters, sufficient for a detailed announcement rather than a brief notice. Hence, the classification is CAP with high confidence.
2026-04-15 English
Rubicon Research Limited Corporate Announcement for Acquisition
Capital/Financing Update Classification · 95% confidence The document is an official notification addressed to stock exchanges (BSE and NSE) regarding the acquisition of an 85% stake in Arinna Lifesciences Limited by Rubicon Research Limited. It references compliance with Regulation 30 of the SEBI Listing Regulations, which pertains to disclosure of material events. The content includes detailed information about the acquisition such as the target entity, industry, consideration, and background, but it is not a financial report or earnings release. It is an announcement of a corporate transaction (acquisition) and not a merger proxy or tender offer filing. Therefore, it fits the category of Capital/Financing Update (CAP) as it relates to a significant change in the company's capital structure through acquisition.
2026-04-15 English
Updates
Regulatory Filings Classification · 95% confidence The document is a certificate issued under Regulation 74(5) of SEBI (Depositories and Participants) Regulations, 2018, confirming compliance related to dematerialisation of securities for the quarter ended March 31, 2026. It is addressed to stock exchanges and the company's compliance officer. The content is a compliance certificate rather than a financial report or announcement of financial results. The document length is 3785 characters, which is relatively short and primarily contains a certification statement. It does not contain financial statements, management discussion, or detailed report data. Therefore, it fits the criteria of a Regulatory Filing (RNS) as it is a regulatory compliance certificate and not a full report or announcement of a report.
2026-04-13 English

Browse filings by year

2 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.